Shareholders' equity (Tables)

12 Months Ended

Dec. 31, 2024

Stockholders' Equity Note [Abstract]

Schedule of Status of Options

		December 31, 2024
		Number of share options				Weighted- average exercise price				Weighted- average remaining contractual term (in years)
Outstanding at the beginning of the year			3,412,281			$	52.52				4.66
Granted			-				-				-
Exercised			(332,461	)			9.97				-
Forfeited			(103,771	)			68.66				-
Outstanding at the end of the year			2,976,049			$	56.78				3.73
Exercisable at the end of the year			2,388,754			$	56.91				3.43

Schedule of Fair Value of Options Estimated on Grant Date

		December 31,
		2024			2023			2022
Volatility		-			56% – 58%			54% – 57%
Expected term in years		-			3.78 – 5.23			3.78 – 4.56
Risk-free interest rate		-			3.37% – 4.22%			1.87% – 4.4%
Estimated fair value of underlying ordinary shares		-			20.5 – 39.35			27.55 – 81.03
Dividend yield		-			0%			0%

Schedule of Status of RSU

		December 31, 2024
		Number of RSUs and PSUs				Weighted- average grant date fair value
Outstanding at the beginning of the year			1,476,818			$	57.76
Granted			2,052,292				27.83
Vested			(833,722	)			55.91
Forfeited			(386,617	)			47.34
Outstanding at the end of the year			2,308,771			$	33.14

Schedule of Fair of Espp Weighted Average Assumptions

		December 31,
		2024			2023			2022
Volatility		46.15-97.6%			66.4-97.6%			86.4-97.6%
Expected term in years		0.5			0.5			0.5
Risk-free interest rate		4.24-5.26%			4.24-4.96%			0.08-4.24%
Estimated fair value of underlying ordinary shares		26.40-206.07			26.40-206.07			35.36-206.07
Dividend yield		0%			0%			0%

Schedule of Stock-Based Compensation Costs

		December 31,
		2024				2023				2022
Cost of revenue		$	2,136			$	2,497			$	2,520
Research and development			23,569				24,310				23,828
Sales and marketing			13,592				13,304				17,196
General and administrative			34,645				28,587				28,211
Total		$	73,942			$	68,698			$	71,755